ANKE BIO(SZ:300009) Xin Lang Cai Jing·2025-09-07 03:28Core Viewpoint - Anke Bio (300009.SZ) announced that senior executive Yao Jianping plans to reduce his shareholding by 1 million shares due to personal financial needs, marking his first reduction in nearly four years [1][2]. Company Overview - Anke Bio, established in September 2000 and listed on the Shenzhen Stock Exchange in October 2009, is a national high-tech enterprise focused on the biopharmaceutical industry, with products including biological products, modern traditional Chinese medicine, chemical synthetic drugs, and peptide drugs [5]. - The company has experienced a long-term downward trend in stock price since its IPO, with a historical high of 64.88 yuan per share, and has not returned to that level since [5]. Financial Performance - In the first half of 2025, Anke Bio reported revenue of 1.29 billion yuan, a year-on-year decline of 0.51%, and a net profit attributable to shareholders of 367 million yuan, down 11.92% year-on-year [6]. - For the full year of 2024, the company experienced a revenue decline of 11.51% to 2.536 billion yuan and a net profit drop of 16.56% to 707 million yuan, marking the first time in its history that both revenue and net profit declined in a complete calendar year [6]. Executive Compensation - Yao Jianping's salary for the previous year was approximately 1.67 million yuan, reflecting an increase of 810,000 yuan compared to the previous year [4].